If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

  • There is currently no data for AGL

Contract Win

27 Jun 2007 07:01

Angle PLC27 June 2007 For Immediate Release 27 June 2007 ANGLE plc ('ANGLE' or the 'Company') ANGLE Awarded Long-term Management Contract with Innovation Lincolnshire Outreach Programme ANGLE plc (AIM:AGL), the intellectual property and technology commercialisationcompany, announces that it has secured a new management contract worth £0.9million over the next 21 months. ANGLE has been appointed to manage the new Innovation Lincolnshire OutreachProgramme which is focussed upon improving business growth and performancewithin the Lincolnshire region. This flagship programme, lasting 21 months, isvalued at £1.7 million. £0.9 million is in fees to ANGLE, with the balance beinggrants to companies and project expenditure. The programme is being establishedto raise the economic performance and aspirations of Lincolnshire's businessesby providing effective support for innovation and entrepreneurship across theCounty. ANGLE was awarded the contract on the basis of its experience working in similarbusiness support programmes, both in the UK and internationally, and thetechniques which it was able to demonstrate have generated measurable innovationbenefits for a range of other SMEs. ANGLE was also able to fulfil a criticalrequirement of the programme, namely to ensure rapid deployment of a team ofprofessional innovation managers with relevant commercial and technicalexperience. The project is being launched in June and ANGLE is already workingwith several of the County's businesses. The aim of the programme is to assist businesses in the County by advising themon key business growth issues including: • ways to become more innovative with their processes; • the conversion of ideas into new products or services; • doing business with suppliers and clients; • identifying new strategies for running businesses. Commenting on the award of this contract, Andrew Newland, Chief Executive ofANGLE, said: "This represents a major contract win for our management services business andunderlines our strategy of focusing on long-term and profitable contracts. Inaddition to generating new revenue for ANGLE it also clearly illustrates theattraction of our business model for SMEs looking to develop and commercialisetheir IP. "We are delighted to have been selected to partner the City of Lincoln Counciland Lincolnshire Enterprise in this new project. Our team is looking forward toworking with Lincolnshire's businesses to help identify new opportunities andsecure business growth through innovation." Enquiries:ANGLE plc +44 (0)1483 295830Andrew Newland, Chief ExecutiveIan Griffiths, Finance Director Buchanan Communications +44 (0)20 7466 5000Richard Darby, Suzanne Brocks,James Strong Notes to Editors Founded in 1994, ANGLE is an international venture management company focusingon the commercialisation of technology and the development of technology-basedindustry. ANGLE creates, develops and advises technology businesses on its ownbehalf and for its clients. ANGLE is listed on AIM (AGL.L); further informationcan be found on www.ANGLEplc.com This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
4th Jan 20177:00 amRNSNotice of Results
28th Nov 20167:00 amRNSISSUE OF SHARE OPTIONS
24th Nov 20162:48 pmRNSResult of GM
4th Nov 20167:00 amRNSBarts Research Supports Potential Use of Parsortix
1st Nov 20167:00 amRNSNotice of GM
27th Oct 20167:00 amRNSDirector's share purchase
7th Oct 201611:57 amRNSHolding(s) in Company
4th Oct 20164:35 pmRNSResult of AGM
30th Sep 20167:00 amRNSResearch published in Clinical Chemistry
19th Sep 201611:14 amRNSIssue of Equity
9th Sep 20164:12 pmRNSAnnual Report and Accounts and Notice of AGM
4th Aug 20167:00 amRNSMD Anderson Cancer Center poster presentation
2nd Aug 20163:37 pmRNSEdison issues ADR update on Angle
28th Jul 20167:00 amRNSUse of Parsortix in GANNET53 drug trial
28th Jul 20167:00 amRNSPreliminary Results
27th Jul 20167:00 amRNSInitiation of 200 patient US ovarian cancer study
19th Jul 20167:00 amRNSInitiation of European ovarian cancer study
15th Jul 20167:00 amRNSNotice of Results
15th Jul 20167:00 amRNSParsortix gaining traction at EACR Conference
1st Jun 20163:04 pmRNSHolding(s) in Company
31st May 20164:36 pmRNSHolding(s) in Company
27th May 20163:12 pmRNSEdison issues research update on Angle
25th May 20167:00 amRNSCancer Research UK Contract
25th May 20167:00 amRNSPlacing
29th Apr 20167:00 amRNSNEW PUBLICATIONS UTILISING PARSORTIX
19th Apr 201612:43 pmRNSEdison issues research update on Angle
18th Apr 20167:00 amRNSParsortix potential in metastatic breast cancer
21st Mar 201612:12 pmRNSEdison issues research update on Angle
21st Mar 20167:00 amRNSParsortix potential for prostate cancer detection
9th Mar 20167:00 amRNSEuropean patent grant for Parsortix
28th Jan 20167:00 amRNSInterim Results
27th Jan 201610:42 amRNSNotice of Interim Results
25th Jan 20167:00 amRNSUKE publishes evaluation of Parsortix
22nd Dec 20157:00 amRNSCompletion of Geomerics Transaction
15th Dec 20157:00 amRNSParsortix first commercial sales
10th Dec 20157:00 amRNSChange of FTSE Industry Classification Benchmark
30th Nov 20155:56 pmRNSHolding(s) in Company
17th Nov 20157:00 amRNSLung Cancer Research Publication
12th Nov 20152:17 pmRNSISSUE OF SHARE OPTIONS
14th Oct 20157:00 amRNSPatent Grant
30th Sep 20155:50 pmRNSResult of AGM
28th Sep 20157:00 amRNSOvarian cancer results
24th Sep 20157:00 amRNSProstrate cancer study published PLOS ONE Journal
9th Sep 20157:00 amRNSBREAST CANCER RESULTS PRESENTED AT CDX CONFERENCE
8th Sep 20153:54 pmRNSAnnual Report and Accounts and Notice of AGM
26th Aug 20151:48 pmRNSIssue of Equity and Total Voting Rights
23rd Jul 20157:00 amRNSFinal Results
20th Jul 20157:00 amRNSNotification of Preliminary Results
8th Jul 20157:00 amRNSAppointment Of Scientific Adviser
11th Jun 20157:00 amRNSBarts Prostate Cancer Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.